Cybin Corp. at Forefront of Change in Psilocybin-Based Treatments

 

• -Company focused on furthering R&D of psilocybin-based medications
• -Cybin believes psychedelic substances derived from mushrooms can work as boosters for brain
• -Psilocybin shows promise for an array of mental health issues

Cybin Corp. is a leading life-science company focused on psychedelic and nutraceutical products to support various psychiatric and neurological conditions. The company is engaged in clinical trials, through a partnership with the Toronto Centre for Psychedelic Science (“TCPS”) to gain regulatory approval for psilocybin and other psychedelic products (http://ibn.fm/RgpQc).

In the 1940s, the study of psychedelic drugs for the treatment of mental health conditions began with the discovery of LSD. However, President Richard Nixon put a stop to this research in the 1960s with his war on drugs. Only recently have researchers began to explore psychedelics once again. This research is showing positive results in the treatment of depression, anxiety, PTSD, addictions, eating disorders, ADHD and more.

This evolution couldn’t be more timely. In the midst of a worldwide pandemic, the need for anxiety-reducing therapies has grown substantially, and psychedelics may have the potential to make a profound impact. Clinical studies for PTSD and psilocybin therapy for treatment-resistant depression has won the acknowledgment of the FDA (http://ibn.fm/V3HpZ). The combined cooperation of the FDA and investors is breaking down previous barriers. Psychedelic treatment may soon become mainstream.

Cybin believes that psychedelic substances derived from mushrooms can work as boosters for the brain, potentially rebuilding pathways and breaking negative patterns. Today more than 700 million people around the world struggle with mental illness, addiction or eating disorders — all areas where the benefits of psychedelic substances is being studied. What’s more, even though over 40 million Americans are taking psychiatric drugs, Big Pharma has not produced any new drug innovations in the last ten years (http://ibn.fm/yuVvc).

The world is changing quickly, and people are looking for new and improved options for managing their health. Right now, only 10% of fungi species are taxonomically classified, leaving an enormous potential for future medical research. Cybin is at the forefront of that research, paving the way for new advances and leveraging its expertise in the world of medicinal mushrooms.

Cybin operates in the functional-mushroom market with a goal to develop fungi-derived medicinal products to treat mental illness and other health conditions. The business model of this early-stage, life-sciences company includes two wholly owned core subsidiaries: Serenity Life Sciences, focusing on advancing research and development of psilocybin-based pharmaceutical products, and Natures Journey Inc., developing medicinal nonpsychedelic nutraceutical products.

For more information about this company, please visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Wrap Technologies, Inc. (NASDAQ: WRTC) to Present to Live Virtual Audience at The LD 500

Wrap Technologies (NASDAQ: WRTC), an innovator of modern policing solutions, today announced its plans to present at the LD 500 investor conference, scheduled to take place from Sept. 1-4, 2020. According to the update, Wrap Technologies’ management will be presenting to a live virtual audience at 10:40 a.m. PT / 1:40 p.m. ET. on Thursday, Sept. 3, and holding one-on-one virtual meetings with institutional investors and analysts throughout the day. The presentation will be webcast live and made available for replay by visiting http://ibn.fm/7PBdO, with a replay of the presentation also available on the company’s website. Interested parties may register for the event via the following link: http://ibn.fm/RZjcq.

To view the full press release, visit http://ibn.fm/YT5kL

About Wrap Technologies, Inc.

Wrap Technologies is an innovator of modern policing solutions. The company’s BolaWrap 100 product is a patented, hand-held remote restraint device that discharges an eight-foot bola style Kevlar(R) tether to restrain an individual at a range of 10-25 feet. Developed by award winning inventor Elwood Norris, the company’s chief technology officer, the small but powerful BolaWrap 100 assists law enforcement to safely and effectively control encounters, especially those involving an individual experiencing a mental crisis. BolaWrap 100 has already been used to safely apprehend suspects without injury by agencies in cities including Los Angeles, Sacramento, Fresno, Bell, Albuquerque, Minneapolis, West Palm Beach, Fort Worth and Oak Ridge. For information about the company, please visit www.WrapTechnologies.com.

NOTE TO INVESTORS: The latest news and updates relating to WRTC are available in the company’s newsroom at http://ibn.fm/WRTC

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Trxade Group, Inc. (NASDAQ: MEDS) Augments B2B Services with New Bundled, COVID-responsive Employee Wellness Package

 

• -Pharmaceutical supplies and services innovator Trxade Group Inc. has announced a new B2B resource that bundles telemedicine services that may prove particularly useful for companies during the ongoing pandemic period
• -Trxade Group’s new Bonum+ platform combines the power of telehealth consultation, AI-driven COVID-19 risk assessment and streamlined personal protective equipment purchasing to help manage employees’ care and performance
• -The company is an emerging web-based presence in the wellness market that builds trust and independent pharmacy purchasing power through drug pricing transparency
• -The company has achieved more than 50 percent penetration among the nation’s approximately 22,000 independent pharmacies.

Trxade Group (NASDAQ: MEDS) is expanding the B2B functionality of its supply chain trading platform through a first-of-its-kind bundled service that combines telehealth performance, a COVID-19 risk assessment tool and a personal protective equipment (“PPE”) purchasing tool to help businesses better deal with the medical needs of their internal corporate structures during an era of pandemic and beyond.

The company’s Bonum+ platform (http://ibn.fm/AAgH9) builds on the Bonum Health Hub wellness brand that has established a web-accessible medical consultation service in conjunction with an online prescription pharmaceutical presence (http://ibn.fm/D0N1Y) and the company’s app-accessible DelivMeds same-day / mail order pharmaceuticals delivery service (http://ibn.fm/wnW0S).

“This platform resolves a fundamental trust problem impacting employer’s safety and security policies, allowing companies to more effectively combat COVID-19 concerns in the workplace,” Bonum Health President Ashton Maaraba stated in the company’s most recent announcement. “Looking forward, we plan to continue to expand the breadth of services offered by Bonum Health, including adding a digital health hub with next-generation prescription concierge services.”

The Bonum+ platform centralizes communication and provides tools for COVID-19 contact tracing that helps companies assess employee risk profiles and respond as necessary with new PPE resources. The platform also offers health recommendations and connects employees with board certified physicians when needed, utilizing integrated artificial intelligence to streamline processes.

Trxade Group has distinguished itself as a web-based presence in the wellness market that emphasizes transparency in the pharmaceutical purchasing pipeline, empowering subscribers to assess drug prices and supply availability to make best product ordering decisions.

The company’s flagship platform has achieved more than 50 percent market penetration in attracting nearly 12,000 of the United States’ estimated 22,000 independent pharmacies so far, helping them to become more competitive with large pharmaceutical retail chains.

“Our platform lets these independents know that they’re receiving a fair price from competing suppliers on fair payment terms and often with next day delivery,” Founder, Chairman and CEO Suren Ajjarapu said in a recent earnings conference call (http://ibn.fm/HDLeo). “We believe this radical price transparency, economy of scale and competition amongst suppliers leads (to) up to 10% reduction in pharmacies’ total annual drug purchase costs, with a drug-level savings of up to 90% on certain pharmaceutical products.”

Trxade Group thereby saves pharmacists from labor-intensive cost comparisons between pharmaceutical distributors on a repetitive basis, profiting through a fee structure similar in nature to the ones employed by merchandising pioneers such as PayPal and Visa.

The company’s second quarter financial report notes that revenues increased 244 percent year-over-year for the quarter, and by 199 percent sequentially from the first quarter of the year.

“We believe that we are well positioned to execute upon the immense opportunity facing us today, supporting critical public health efforts nationwide,” Maaraba stated.

For more information, visit the company’s website at www.TrxadeGroup.com.

NOTE TO INVESTORS: The latest news and updates relating to MEDS are available in the company’s newsroom at http://ibn.fm/MEDS

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Predictive Oncology Inc. (NASDAQ: POAI) and TumorGenesis Advancing Path Toward Patient-Specific Treatments

 Predictive Oncology (NASDAQ: POAI), together with its TumorGenesis subsidiary, has achieved significant breakthroughs in applying data and artificial intelligence (“AI”) to personalized medicine and drug discovery. Earlier in June, TumorGenesis, which is developing a new rapid approach to growing tumors in the laboratory, sold its first order of unique ovarian cancer cell culture media to a New England-based university carrying out research within the sector (http://ibn.fm/lpsCk). A recent article discussing POAI and TumorGenesis reads, “Predictive Oncology focuses on building AI-driven predictive models of tumor drug response and outcomes from its database of drug-response and genomic profiles gathered from more than 150,000 cancer cases. The company’s wholly owned TumorGenesis subsidiary specializes in the field of ovarian cancer, creating laboratory-grown cancer cells to be used in assisting researchers and clinicians identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified, they feed into TumorGenesis’ proprietary Oncology Capture Technology Platform, which isolates and helps categorize an individual patient’s heterogeneous tumor sample to enable the development of a patient-specific treatment plan (http://ibn.fm/lpsCk).”

To view the full article, visit http://ibn.fm/g222t

About Predictive Oncology Inc.

Predictive Oncology operates through three segments (domestic, international and other), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions by providing an evidence-based road map for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s Skyline Medical division markets its patented and FDA-cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Sigma Labs Inc. (NASDAQ: SGLB) Announces Participation Schedule for September Investor Conferences

 Sigma Labs (NASDAQ: SGLB), a leading developer of quality assurance software for the additive manufacturing industry, recently announced its plans to participate in investor conferences during the month of September 2020. According to the update, SGLB will participate in the LD 500 Virtual Investor Conference slated to take place from September 1-4, 2020, and the H.C. Wainwright 22nd Annual Global Investment Conference on September 14-16, 2020. Sigma Labs CEO Mark K. Ruport will host a virtual presentation and participate in one-on-one meetings, and management will highlight its recent contract award with Mitsubishi Heavy Industries and other end users in a newly launched program.

To view the full press release, visit http://ibn.fm/FJW8h

About Sigma Labs Inc.

Sigma Labs is a leading provider of quality assurance software to the commercial 3D metal printing industry under the PrintRite3D(R) brand. Sigma specializes in the development and commercialization of real-time monitoring solutions known as PrintRite3D for 3D metal advanced manufacturing technologies. PrintRite3D detects and classifies defects and anomalies real-time during the manufacturing process and informs the production manager of quality issues. Sigma Labs’ software product is a major catalyst for the acceleration and adoption of 3D metal printing. For more information, please visit www.SigmaLabsInc.com.

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – Cybin Corp. Poised Amid Groundbreaking Decision to Allow Psilocybin Therapy

 Cybin Corp., an exemplary Canada-based life-science company focused on the development of pharmaceutical-grade psilocybin products, appears ideally positioned to leverage a milestone moment. Canada’s Minister of Health, the Honourable Patty Hajdu, recently approved the use of psilocybin therapy in the end-of-life treatment of four Canadians battling incurable cancer (http://ibn.fm/0BUOU), and this groundbreaking decision bodes well for companies such as Cybin, which are operating in the sector. The approval marks the first known, legal medical exemption for psilocybin use in Canada since the compound became illegal in the country in 1974. A recent article discussing this anticipates more applications through the exemption process and quotes one of the applicants, Laurie Brooks, on the approval, who stated, “I want to thank the Health Minister and Health Canada for approving my request for psilocybin use. The acknowledgment of the pain and anxiety that I have been suffering with means a lot to me, and I am feeling quite emotional . . . as a result. I hope this is just the beginning and that soon all Canadians will be able to access psilocybin for therapeutic use, to help with the pain they are experiencing without having to petition the government for months to gain permission.”

To view the full article, visit http://ibn.fm/avcDX

About Cybin Corp.

Cybin is a mushroom life-science company advancing psychedelic and nutraceutical-based products. The company expects to launch psilocybin-based products in jurisdictions where the substance is not prohibited. Simultaneously, the company is structuring and supporting clinical studies across North America and other regions through strategic academic and institutional partnerships. For more information, visit www.Cybin.com.

NOTE TO INVESTORS: The latest news and updates relating to Cybin are available in the company’s newsroom at http://ibn.fm/Cybin

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

MissionIRNewsBreaks – DarioHealth Corp. (NASDAQ: DRIO) Positioned to Compete in ‘Largely Untapped US Market’

 DarioHealth (NASDAQ: DRIO), a global digital-therapeutics company serving its users with dynamic mobile-health solutions, recently completed a round of successful fundraising that will assist in expanding the availability of its platform. DarioHealth secured approximately $28.6 million in aggregate gross proceeds from health-care funds and institutions across the United States and Israel through the private-placement transaction with accredited investors. The new capital coupled with existing cash  puts the company in its best financial state since its inception (http://ibn.fm/uKWvc). A recent article discussing this quotes Dario CEO Erez Raphael, who stated, “We are pleased to have the confidence of our largest shareholder and several new highly regarded health-care investors as we expand commercial to manage existing and anticipated near-term agreements with health-care payers. The adoption rate of digital therapeutics has been accelerated by the current pandemic. Dario’s efficacious, value-oriented solution is well-positioned to compete in this largely untapped U.S. market.”

To view the full article, visit http://ibn.fm/OosnP

About DarioHealth Corp.

DarioHealth is a leading, global, digital-therapeutics company revolutionizing the way people with chronic conditions manage their health. By delivering evidence-based interventions that are driven by data, high-quality software and coaching, the company empowers individuals to make healthy adjustments to their daily lifestyle choices to improve their overall health. The company’s cross-functional team operates at the intersection of life science, behavioral science and software technology to deliver highly engaging therapeutic interventions. Dario offers one of the highest-rated diabetes solutions in the market, and its user-centric MyDario(TM) mobile app is loved by tens of thousands of consumers around the globe. DarioHealth is rapidly moving into new geographic markets to address chronic conditions using a performance-based approach to improve the health of users managing chronic disease. To learn more about DarioHealth and its digital health solutions, visit  www.DarioHealth.com.

NOTE TO INVESTORS: The latest news and updates relating to DarioHealth are available in the company’s newsroom at http://ibn.fm/DRIO  

About MissionIRNewsBreaks

MissionIRNewsBreaks provide a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by our Team of professional journalists that keep a constant eye on the markets, these posts are designed to inform you on the latest happenings of our clients and other publicly traded companies on our radar. From earnings, acquisitions and agreements to conference attendance and clinical study results, our news breaks keep you up-to-date with the day’s top movers. MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html

Predictive Oncology Inc.’s (NASDAQ: POAI) Exclusive Resources Provide Personal Profiling, Tools to Improve Patient Outcomes

 

• -POAI, Helomics builds AI-driven models that predict drug response, patient outcome
• -Company tests patient tumor, generates comprehensive picture that oncologists use to individualize therapy
• -Key to individualized insight is POAI’s Tumor Drug Response Profiling (“TDRP”) platform, NGS-based genomic profiling, unmatched cancer knowledge base

Guided by the mantra that “cancer is personal — we believe therapy should be too,” Predictive Oncology (NASDAQ: POAI) subsidiary Helomics focus on building AI-driven models that will predict drug response and patient outcome of individual tumors. With the largest tumor inventory in the world, POAI leads the way in providing a functional precision medicine approach that harnesses the power of an individual patient’s tumor to personalize their cancer treatment plan.

POAI works closely with oncologists to provide key information to help improve their patients’ odds in their fight against cancer. Helomics current clinical test platform offers a powerful, proprietary approach that tests a patient’s unique tumor, then combines drug-response profiling and genomic profiling of that tumor to generate a comprehensive picture that an oncologist can use to individualize therapy and improve positive outcomes.

Oncologists rely on these personalized profiles to help reduce the risk that a patient receives ineffective therapies as well as to identify alternatives when a typical treatment recommended for certain types of cancer cannot be tolerated.

A key component in Predictive Oncology’s ability to offer such individualized insight is the company’s Tumor Drug Response Profiling (“TDRP”) platform, which it combines with the latest NGS-based genomic profiling and POAI’s vast cancer knowledge-base of 150,000 tumors. Exclusive to POAI, these resources provide a more functional approach to precision medicine and allow an oncologist to reach beyond genomics alone in providing cancer-treatment recommendations.

In addition, every tumor tested by POAI and Helomics adds data to the company’s unparalleled D-CHIP knowledgebase, which contains anonymized molecular and drug-response profiles from more than 150,000 cancer cases. This invaluable information provides researchers in pharma, biopharma and diagnostic companies actionable insights to help discover better targeted therapies as well as contribute to key developments in clinical trials, companion diagnostics, and biomarkers.

POAI is bringing precision medicine, or tailored medical treatment using the individual characteristics of each patient, to the treatment of cancer. Through the company’s Helomics division, the company leverages its unique, clinically validated patient derived (“PDx”) smart tumor profiling platform to provide oncologists with a road map to help individualize therapy. In addition, the company is utilizing artificial intelligence and its proprietary database of over 150,000 cancer cases tumors to build AI-driven models of tumor drug response to improve outcomes for the patients of today and tomorrow

For more information about the company, visit www.Predictive-Oncology.com.

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html